MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1093/jjco/hyag074

Медицинская библиотека · Japanese journal of clinical oncology · 2026

Clinical utility of tumour markers in skeletal metastasis of unknown primary at the initial visit.

Yamaga Kensaku, Akahori Keiichi, Osaki Mari, Nagashima Hideki

СтатьяПеревод в очереди

Аннотация

BACKGROUND

Skeletal metastasis of unknown primary at the initial visit represents a clinically important subset of metastatic bone tumours, accounting for ~7.8%-21.7% of all skeletal metastases. This condition differs from cancer of unknown primary (CUP), in which the primary site remains unidentified after comprehensive evaluation. At this diagnostic entry point, before completion of a full work-up, early stratification is essential; however, the clinical utility of serum tumour markers at this stage remains unclear.

METHODS

We retrospectively reviewed 79 patients who presented with skeletal metastasis of unknown primary at the initial visit before diagnostic work-up between January 2010 and October 2023. Clinical characteristics, final primary diagnoses, types of tumour markers measured, positivity rates, and diagnostic performance were analysed.

RESULTS

Haematologic malignancies were the most frequent final diagnoses (40.5%), followed by lung (22.8%) and prostate cancer (10.1%). A total of 17 tumour markers were measured (mean, 6.3 per patient; range, 0-12). Prostate-specific antigen (PSA), immunoelectrophoresis (IEP), soluble interleukin-2 receptor (sIL-2R), and thyroglobulin (Tg) showed high sensitivity and specificity for prostate cancer, multiple myeloma, malignant lymphoma, and thyroid cancer, respectively. Carcinoembryonic antigen (CEA) and cytokeratin 19 (CK19, CYFRA 21-1), although not organ-specific, were frequently positive in carcinomas and served as indicators of epithelial malignancy.

CONCLUSIONS

Serum tumour markers can assist early diagnostic stratification at the initial presentation of skeletal metastasis before primary-site identification. A selective testing strategy focusing on sIL-2R, IEP, CEA, and CK19, with PSA added in men and Tg when clinically indicated, may improve diagnostic efficiency and provide a basis for considering a bone-metastasis-oriented diagnostic approach.

Для цитирования: Yamaga Kensaku, Akahori Keiichi, Osaki Mari, Nagashima Hideki. Clinical utility of tumour markers in skeletal metastasis of unknown primary at the initial visit.. Japanese journal of clinical oncology. 2026. DOI: 10.1093/jjco/hyag074.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.